Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in Semin Oncol

Retrieve available abstracts of 8 articles:
HTML format



Single Articles


    February 2020
  1. ORONSKY B, Reid T, Larson C, Knox SJ, et al
    Locally advanced rectal cancer: The past, present, and future.
    Semin Oncol. 2020;47:85-92.
    PubMed     Abstract available


    June 2019
  2. YAMAMOTO H, Imai K
    An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine.
    Semin Oncol. 2019;46:261-270.
    PubMed     Abstract available


    February 2019
  3. FOJO AT
    Immunotherapy for adrenocortical cancer.
    Semin Oncol. 2019;46:1-2.
    PubMed    


    June 2018
  4. CASEY RT, Giger O, Seetho I, Marker A, et al
    Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
    Semin Oncol. 2018;45:151-155.
    PubMed     Abstract available


  5. SCHIRRIPA M, Cohen SA, Battaglin F, Lenz HJ, et al
    Biomarker-driven and molecular targeted therapies for colorectal cancers.
    Semin Oncol. 2018;45:124-132.
    PubMed     Abstract available


    June 2017
  6. BAS Y, Hassan HA, Adiguzel C, Bulur O, et al
    The distribution of cancer cases in Somalia.
    Semin Oncol. 2017;44:178-186.
    PubMed     Abstract available


    April 2017
  7. DUCREUX M, Osterlund P, Pignon JP
    Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?
    Semin Oncol. 2017;44:129-131.
    PubMed    


  8. CHEBIB R, Verlingue L, Cozic N, Faron M, et al
    Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Semin Oncol. 2017;44:114-128.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: